Aquestive Therapeutics (Formerly known as MonoSolRx)

163 articles with Aquestive Therapeutics (Formerly known as MonoSolRx)

• Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences

  6/9/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in two upcoming investor conferences in June.

• Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference

  5/11/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference

• Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/4/2021

  Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent developments in its business.

• Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET

  4/21/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for first quarter ended March 31, 2021

• Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

  3/25/2021

  Provides in-depth scientific and clinical data in R&D event today at 9:00 am ET Outlines data from two completed Phase 1 pharmacokinetic (PK) trials for AQST-108 (dipivefrin) sublingual film Articulates development strategy for second prodrug candidate, AQST-109 sublingual film Provides details on potential patent coverage to at least 2037

• Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  3/9/2021

  Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America Sympazan ® (clobazam) continues to meet key performance metrics Management to host conference call and webcast at 8:00 a.m

• Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET

  3/5/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET.

• Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback

  2/25/2021

  Reaffirms plans to resubmit its New Drug Application (NDA) around the end of second quarter 2021 Received additional feedback from FDA after completion of Type A meeting and submission of revised weight based dosing regimen Anticipates an FDA action date in 2021

• Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET

  2/17/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for the fourth quarter and year ended December 31, 2020 and provide a business update after market close on Tuesday, March 9, 2021. Management will host a conference call for investors at 8:00 a.m. ET o

• Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

  2/9/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors

• Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

  1/28/2021

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Mark Lepore, MD, as the Chief Medical Officer for Allergy.

• Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

  1/21/2021

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN ™  (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).  

• Aquestive Therapeutics Provides Business Update

  1/7/2021

  Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committed Multiple clinical trials demonstrate that AQST-108 can consistently deliver epinephrine

• Aquestive Therapeutics to Present at Two Upcoming Investor Conferences - Jan 04, 2021

  1/4/2021

  Aquestive Therapeutics, Inc. announced that the management team will participate in fireside chats at the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, and at the Westwicke Healthcare Day to be held virtually on January 14 during the ICR Conference 2021.

• Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer

  12/16/2020

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that John Maxwell, Senior Vice President, Chief Financial Officer (CFO) of the Company,

• Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/25/2020

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020.

• Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ MonetizationReceives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million

  11/23/2020

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today receipt of the first milestone payment of $10 million under the previously announced royalty monetization agreement with an affiliate of Marathon Asset Management,

• Aquestive Therapeutics Completes FDA Type A Meeting on Libervant

  11/18/2020

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) confirming a pathway for resubmission for approval of the Company’s drug candidate Libervant

• Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/4/2020

  Sympazan® (clobazam) continues to meet key performance metrics and market penetration FDA Type A meeting for Libervant™ (diazepam) Buccal Film scheduled for November 12, 2020 Completed dosing in Phase 1 Pharmacokinetic (PK) trial for AQST-108 (epinephrine) Execution of monetization agreement providing up to $125 million for royalty rights in KYNMOBI™ (apomorphine HCI)

• Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million

  11/3/2020

  Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has entered a royalty monetization agreement with an affiliate of Marathon Asset Management, a leading global investment firm (“Marathon”)